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The Notch pathway is an attractive therapeutic target for treatment of cancer and T cell-mediated pathology,
but Notch inhibition leads tomany side effects. Pinnell et al. (2015) demonstrate that oncogenic functions can
be separated biochemically from other functions of Notch, opening new options for more selective targeting
of this pathway.A simpler signaling pathway than the
Notch pathway can hardly be found: liga-
tion by a membrane-bound ligand leads
to proteolytic release of the intracellular
domain of Notch (ICN) by a g-secretase;
the ICN moves to the nucleus and,
together with the sequence-specific tran-
scription factor RBPJ (also known asCSL)
and the MAML coactivator, induces tran-
scription of target genes (Figure 1; Wang
et al., 2015). No intermediates, no bifurca-
tions; basically a straight connection from
the plasma membrane to the nucleus.
It is equally difficult to name a tissue
where Notch does not play an important
role. The pathway is most famous for its
role in differentiation processes, but it
also controls decisions of cellular life and
death as well as proliferation. Notch has
prominent functions in the immune sys-
tem (Radtke et al., 2013). It is critical for
development of T cells in the thymus, con-
trols differentiation of dendritic cell and
innate lymphoid cell subsets, and regu-
lates effector differentiation of mature
T cells, to name just a few of its many
functions.
Notch is also an important oncogene. It
is in fact the major oncogene in T lineage
acute lymphoblastic leukemia (T-ALL), a
sinister echo of the major role Notch plays
in early T cell development. Activating
mutations in NOTCH1 (one of four Notch
genes in mammals) are present in more
than half of T-ALLs and most of these
stop growing in the presence of inhibitors
of Notch (South et al., 2012). A host of
other cancers, including various B cell
malignancies, melanoma, and ovarian
cancer, also depend on Notch signaling
(South et al., 2012). Notch is therefore an
attractive therapeutic target, but the
question is, how can you avoid the pre-
dictable side effects from inhibiting this
widely used pathway?Drugs that inhibit general activation of
Notch, g-secretase inhibitors (GSI), do
indeed elicit severe side effects. The
most acute present in the intestine (diar-
rhea), because Notch controls differentia-
tion of the constantly renewing enteric
epithelium. These side effects might be
limited by combination therapy with GSI
and glucocorticoids or by the use of anti-
bodies that selectively prevent activation
of individual Notch receptors (Real et al.,
2009; Wu et al., 2010). Still, even with
these modifications, other side effects
are likely, especially with extended treat-
ment. Ideally, one would like to be able
to inhibit only the oncogenic—not the
physiological—functions of Notch.
Is this possible with such a monolithic
pathway, however? Indications exist that
different functions of Notch might actually
be separable. Despite its apparent
simplicity, the outcome of Notch signaling
is not always the same. This is illustrated
most strikingly by the fact that Notch
acts as an oncogene in some cell types,
but paradoxically functions as a tumor
suppressor in others (South et al., 2012).
Furthermore, the target genes of Notch
vary widely among cell types (Wang
et al., 2015). Mechanisms that dictate
target gene specificity of the pathway
must therefore exist. If specific mecha-
nisms exist that determine transactiva-
tion of oncogenic target genes, such
mechanisms might be amenable to
cleaner targeting than general inhibition
of Notch.
The article by Pinnell et al. (2015) in this
issue of Immunity now addresses this
possibility. In a tour de force, using a stun-
ning variety of sophisticated techniques,
the authors of this study identified the
PIAS protein Zmiz1 as a context-specific
coactivator of the ICN-RBPJ complex. In-
dications for a functional interaction ofImmunity 43, NNotch and Zmiz1 first came from their
finding that conditional deletion of Zmiz1
in murine hematopoietic stem cells
(HSCs) phenocopied Notch1 deficiency
with regard to thymocyte development.
Deletion of Zmiz1 also inhibited develop-
ment and progression of T-ALL induced
by expression of oncogenic Notch alleles.
Vice versa, overexpression of Zmiz1
boosted proliferation of a Notch-depen-
dent T-ALL cell line.
The oncogenic function of Zmiz1 de-
pended on the presence of its N-terminal
domain, which was shown, by crystallog-
raphy, to contain a protein-protein inter-
action motif known as tetratricopeptide
(TRP) repeats. Using this TRP domain as
bait, the authors then affinity purified in-
teracting proteins and found by mass
spectrometry that Notch1 associated
with this domain. This was surprising,
because the same authors had previously
reported that Zmiz1 and ICN did not
directly interact (Rakowski et al., 2013).
However, through a series of experi-
ments, including analysis of NMR spectra
of individual and mixed recombinant pro-
teins, they make a compelling case that
the TRP domain of Zmiz1 does bind
directly to the RAM domain of ICN1 (the
intracellular tail of Notch1) after all.
Further results pointed to a role for
Zmiz1 as a cofactor for Notch: like Notch,
Zmiz1 regulated expression ofMyc, a crit-
ical oncogenic target of Notch. Moreover,
Zmiz1 and ICN1 synergistically transacti-
vated a Notch-responsive luciferase re-
porter construct. Zmiz1 was, however,
not required for expression of all Notch
target genes. This was already indicated
by the finding that deletion of Zmiz1 in
HSC did not fully phenocopy the loss of
Notch1. Furthermore, high throughput
gene expression analysis in both human
and murine T-ALL lines revealed thatovember 17, 2015 ª2015 Elsevier Inc. 831
Figure 1. Notch Uses Different Cofactors for Transactivation of Different Genes
Shown is the heterodimeric Notch receptor at the cell surface with its intracellular domain structure and
part of its extracellular regions. Asterisks indicate regions of Notch where oncogenic mutations are found.
Also shown are three types of transcription factor binding regions as described by Pinnell et al. (2015).
Although only Ets is shown, binding elements for bHLH and Runx are also enriched in type B and C sites.
A black arrow indicates the interface between the TRP domain of Zmiz1 and the RAM domain of ICN,
whichmight serve as a target for drugs that inhibit oncogenic, but not general, functions of Notch. The blue
protein X on the type A site indicates a speculative alternative cofactor for Notch.
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less than half of Notch target genes in a
T-ALL cell line.
The selective requirement for Zmiz1 is
at least partially explained by its selective
recruitment. By a series of chromatin
immunoprecipitation (ChIP) experiments,
the authors showed that Zmiz1 did not
bind to all sites occupied by the ICN-
RBPJ complex. Using a search algorithm
for transcription factor binding sites, the
authors distinguished three types of sites.
In type A sites, only RBPJ and ICN were
recruited, but not Zmiz1. In type B sites,
RBPJ, ICN, and Zmiz1 were jointly re-
cruited, and in type C sites Zmiz1, but
not the other two factors, were present.
The latter two types of sites (B and C)
were enriched for adjacent bHLH, Ets,
and Runx sites, suggesting that transcrip-
tion factors of these families favor recruit-
ment of Zmiz1, even in the absence of
ICN. Ets and Zmiz1 did indeed interact,
through another domain of Zmiz1 than
the TRP domain that bound to ICN.
Perhaps the affinity of Zmiz1 for ICN by
itself is weak such that other Zmiz1 bind-
ing factors (such as Ets) are required to832 Immunity 43, November 17, 2015 ª2015help stabilize the interaction between
these two factors.
One thing to note here is that the
number of genes that bound both Zmiz1
and ICN/RBPJ exceeded the number of
Zmiz1-dependent target genes of Notch.
Although selective recruitment is an
attractive explanation for the selective
requirement of Zmiz1, additional layers
of regulation must therefore exist.
The findings by Pinnell et al. (2015)
constitute an important conceptual
advance, because they demonstrate that
the functions of Notch can be separated
biochemically (Figure 1). A major remain-
ing question is why Zmiz1 is necessary
for transactivation of some but not other
target genes of Notch. Earlier studies
had shown that the ICN-RBPJ complex
recruits a number of proteins, which
together take care of three activities
required for activation of transcription:
nucleosome remodeling (enzymes of the
PBAF complex), modification of histones
(acetyl transferases, demethylases, ubiq-
uitin ligase), and recruitment of RNA poly-
merase II (traditional coactivators) (Yatim
et al., 2012). The precise nature of theElsevier Inc.contribution of Zmiz1 in this spectrum is
not clear. Would Zmiz1 bring in a funda-
mentally different activity that is required
in only certain target genes or does
Zmiz1 replace one or more of the previ-
ously identified cofactors of Notch in spe-
cific genes? A related question is whether
there are yet other selective cofactors of
Notch.
Conceptual considerations aside, the
findings by Pinnell et al. (2015) might
lead to novel therapeutic opportunities.
Proof of principle is provided by the
finding that expression of the TRP domain
of Zmiz1, which would interfere with the
interactions between Notch and Zmiz1,
suppressed growth of a T-ALL line. The
beauty of targeting the interaction be-
tween Zmiz1 and ICN would be that only
a subset of Notch target genes would be
affected. Of course it is unlikely that this
subset will be conveniently restricted
only to oncogenic genes. However, the
fact that deletion of Zmiz1 in intestinal
epithelium of mice failed to elicit overt
pathology suggests that at least this
complication of general inhibition of
Notch would be avoided. Targeting the
interaction between Zmiz1 and Notch is
also preferable over general targeting of
Zmiz1, because this factor has prominent
Notch-independent functions. Important
in this regard might be the finding that
the TRP domain, which is necessary for
interaction with ICN, does not seem to
generally be required for Zmiz1 function
(Pinnell et al., 2015).
Inhibition of intracellular protein-protein
interactions is not straightforward,
because the interfaces are generally too
large to be blocked by small molecules.
Nonetheless, recent advances based on
peptide stapling technology have yielded
cell-permeable peptides that assume
proper folding, possess increased pro-
teolytic stability, and effectively inhibit
protein-protein interactions (He et al.,
2015). It seems therefore that the technol-
ogy exists for successful targeting of the
interaction between Zmiz1 and ICN.
Thus far, the elegant simplicity and
broad physiological usage of the pathway
have allowed rogue (oncogenic) versions
of Notch to hold the rest of the body hos-
tage. However, as Pinnell et al. (2015) pro-
vide us with a closer look at Notch, we
gradually start to appreciate that its
harness of simplicity, seemingly impene-
trable from afar, in fact consists of
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plate, brassard, and helmet. The connec-
tions between these elements might be
more vulnerable to a sword of therapy
than originally thought.
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It once seemed clear that negative selection of self-specific T cells in the thymuswas themajormechanism of
central tolerance. But recent studies, including Legoux et al. (2015) in this issue of Immunity, show that this is
not always the case.It’s hard to think of a subject over which
more ink has been spilled in immunology
than the dilemma of how organisms
fortunate enough to have an adaptive
immune system distinguish self from
non-self. This has been debated almost
since the field began, when Ehrlich
mused over how antisera, with their
diverse specificities, could somehow
avoid what he called ‘‘horror autotoxis,’’
or self reactivity (Silverstein, 2001). Fast
forward to the 1950s, and with the clonal
selection theory, Burnet proposed that
self-specific lymphocytes were disposed
of, or clonally deleted (Burnet, 1957). De-
cades later, Nossal found evidence that
specific B cells could also be inacti-
vated, at least in vitro, which he referred
to as ‘‘clonal anergy’’ (Nossal and Pike,
1980). So there seemed to be at least
two competing models for how organ-
isms dealt with self-specific lympho-
cytes: either during their maturation,
also known as central tolerance, or in
the periphery, known as peripheral toler-
ance. In the T cell world, clonal deletion
became known as ‘‘negative selection,’’to distinguish it from ‘‘positive selec-
tion,’’ which is the process by which
T cells are selected to be able to recog-
nize peptide antigens in the context of
one’s own major histocompatibility com-
plex (MHC) molecules. Late in the 1980s,
a series of dramatic papers, based on
either endogenous superantigen effects
or T cell receptor transgenic mice,
showed the wholesale deletion of self-
specific T cells in the thymus, basically
expunging any thoughts of anergy being
a viable option for central tolerance
(Goodnow and Ohashi, 2013). Interest-
ingly, at the same time, Goodnow and
colleagues showed equally dramatic ev-
idence of clonal anergy in an immunolo-
globulin transgenic system (Goodnow
et al., 1989), but this didn’t seem to
have any influence on the T cell commu-
nity. Instead, the issue seemed to be
settled that, at least with respect to
thymocyte maturation, it was all about
negative selection getting rid of all, or
almost all, of the ‘‘dangerous’’ T cells.
But even then, cracks began appearing
in that certainty. First, it was demon-strated that self antigens, at least in
mouse models, could trigger autoimmu-
nity, but most thought these were the
exception rather than the rule. Another
warning sign emerged when Jensen
et al. showed that, whereas work with
TCR transgenics had showed that gd
T cells specific for a minor histocompat-
ibility gene were negatively selected in
the presence of that molecule in vivo,
analysis using a tetramer reagent in
wild-type mice found no evidence of
negative selection (Jensen et al., 2008).
Although there had been hints of trans-
genic artifacts before, this was the first
indication that things could go seriously
wrong in terms of the earlier interpreta-
tion. More recently, my own group, as
well as others, has found that self-spe-
cific T cells are quite abundant in the pe-
riphery of healthy individuals, human or
mouse, although when self versus non-
self can be compared directly with the
same tetrameric reagents, as in the
case of the male antigen H-Y (or,
SmcY), there is, at least in the human
case, a significant (33) reduction in theovember 17, 2015 ª2015 Elsevier Inc. 833
